459 related articles for article (PubMed ID: 12111649)
21. [Study on prognostic significances of different cytogenetic risk categories in patients with primary myelodysplastic syndromes].
Qu SQ; Liu XP; Xu ZF; Zhang Y; Qin TJ; Zhang TJ; Cui R; Hao YS; Xiao ZJ
Zhonghua Xue Ye Xue Za Zhi; 2011 Dec; 32(12):819-24. PubMed ID: 22339954
[TBL] [Abstract][Full Text] [Related]
22. Identification of novel cytogenetic markers with prognostic significance in a series of 968 patients with primary myelodysplastic syndromes.
Solé F; Luño E; Sanzo C; Espinet B; Sanz GF; Cervera J; Calasanz MJ; Cigudosa JC; Millà F; Ribera JM; Bureo E; Marquez ML; Arranz E; Florensa L
Haematologica; 2005 Sep; 90(9):1168-78. PubMed ID: 16154839
[TBL] [Abstract][Full Text] [Related]
23. Is International Prognostic Scoring System (IPSS) still standard in predicting prognosis in patients with myelodysplastic syndrome? External validation of the WHO Classification-Based Prognostic Scoring System (WPSS) and comparison with IPSS.
Park MJ; Kim HJ; Kim SH; Kim DH; Kim SJ; Jang JH; Kim K; Kim WS; Jung CW
Eur J Haematol; 2008 Nov; 81(5):364-73. PubMed ID: 18637029
[TBL] [Abstract][Full Text] [Related]
24. Additional prognostic value of bone marrow histology in patients subclassified according to the International Prognostic Scoring System for myelodysplastic syndromes.
Verburgh E; Achten R; Maes B; Hagemeijer A; Boogaerts M; De Wolf-Peeters C; Verhoef G
J Clin Oncol; 2003 Jan; 21(2):273-82. PubMed ID: 12525519
[TBL] [Abstract][Full Text] [Related]
25. Partial and total monosomal karyotypes in myelodysplastic syndromes: comparative prognostic relevance among 421 patients.
Belli CB; Bengió R; Aranguren PN; Sakamoto F; Flores MG; Watman N; Nucifora E; Prates MV; Arbelbide J; Larripa I
Am J Hematol; 2011 Jul; 86(7):540-5. PubMed ID: 21674572
[TBL] [Abstract][Full Text] [Related]
26. Refinement of the international prognostic scoring system (IPSS) by including LDH as an additional prognostic variable to improve risk assessment in patients with primary myelodysplastic syndromes (MDS).
Germing U; Hildebrandt B; Pfeilstöcker M; Nösslinger T; Valent P; Fonatsch C; Lübbert M; Haase D; Steidl C; Krieger O; Stauder R; Giagounidis AA; Strupp C; Kündgen A; Mueller T; Haas R; Gattermann N; Aul C
Leukemia; 2005 Dec; 19(12):2223-31. PubMed ID: 16193087
[TBL] [Abstract][Full Text] [Related]
27. Validation of the new comprehensive cytogenetic scoring system (NCCSS) on 630 consecutive de novo MDS patients from a single institution.
Bernasconi P; Klersy C; Boni M; Cavigliano PM; Dambruoso I; Zappatore R
Am J Hematol; 2013 Feb; 88(2):120-9. PubMed ID: 23349006
[TBL] [Abstract][Full Text] [Related]
28. Comparison of hypoplastic myelodysplastic syndrome (MDS) with normo-/hypercellular MDS by International Prognostic Scoring System, cytogenetic and genetic studies.
Huang TC; Ko BS; Tang JL; Hsu C; Chen CY; Tsay W; Huang SY; Yao M; Chen YC; Shen MC; Wang CH; Tien HF
Leukemia; 2008 Mar; 22(3):544-50. PubMed ID: 18094713
[TBL] [Abstract][Full Text] [Related]
29. Coalesced multicentric analysis of 2,351 patients with myelodysplastic syndromes indicates an underestimation of poor-risk cytogenetics of myelodysplastic syndromes in the international prognostic scoring system.
Schanz J; Steidl C; Fonatsch C; Pfeilstöcker M; Nösslinger T; Tuechler H; Valent P; Hildebrandt B; Giagounidis A; Aul C; Lübbert M; Stauder R; Krieger O; Garcia-Manero G; Kantarjian H; Germing U; Haase D; Estey E
J Clin Oncol; 2011 May; 29(15):1963-70. PubMed ID: 21519021
[TBL] [Abstract][Full Text] [Related]
30. Revised International Prognostic Scoring System (IPSS) predicts survival and leukemic evolution of myelodysplastic syndromes significantly better than IPSS and WHO Prognostic Scoring System: validation by the Gruppo Romano Mielodisplasie Italian Regional Database.
Voso MT; Fenu S; Latagliata R; Buccisano F; Piciocchi A; Aloe-Spiriti MA; Breccia M; Criscuolo M; Andriani A; Mancini S; Niscola P; Naso V; Nobile C; Piccioni AL; D'Andrea M; D'Addosio A; Leone G; Venditti A
J Clin Oncol; 2013 Jul; 31(21):2671-7. PubMed ID: 23796988
[TBL] [Abstract][Full Text] [Related]
31. Primary myelodysplastic syndromes: analysis of prognostic factors in 235 patients and proposals for an improved scoring system.
Aul C; Gattermann N; Heyll A; Germing U; Derigs G; Schneider W
Leukemia; 1992 Jan; 6(1):52-9. PubMed ID: 1736014
[TBL] [Abstract][Full Text] [Related]
32. International MDS risk analysis workshop (IMRAW)/IPSS reanalyzed: impact of cytopenias on clinical outcomes in myelodysplastic syndromes.
Kao JM; McMillan A; Greenberg PL
Am J Hematol; 2008 Oct; 83(10):765-70. PubMed ID: 18645988
[TBL] [Abstract][Full Text] [Related]
33. Impact of the revised International Prognostic Scoring System, cytogenetics and monosomal karyotype on outcome after allogeneic stem cell transplantation for myelodysplastic syndromes and secondary acute myeloid leukemia evolving from myelodysplastic syndromes: a retrospective multicenter study of the European Society of Blood and Marrow Transplantation.
Koenecke C; Göhring G; de Wreede LC; van Biezen A; Scheid C; Volin L; Maertens J; Finke J; Schaap N; Robin M; Passweg J; Cornelissen J; Beelen D; Heuser M; de Witte T; Kröger N;
Haematologica; 2015 Mar; 100(3):400-8. PubMed ID: 25552702
[TBL] [Abstract][Full Text] [Related]
34. Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System.
Kantarjian H; O'Brien S; Ravandi F; Cortes J; Shan J; Bennett JM; List A; Fenaux P; Sanz G; Issa JP; Freireich EJ; Garcia-Manero G
Cancer; 2008 Sep; 113(6):1351-61. PubMed ID: 18618511
[TBL] [Abstract][Full Text] [Related]
35. [An analysis of prognostic factors in 80 myelodysplastic syndrome].
Xu XQ; Wang JM; Lu SQ; Chen L; Yang JM; Zhang WP; Song XM; Xu YQ; Gong SL; Hou J; Ni X
Zhonghua Xue Ye Xue Za Zhi; 2008 Nov; 29(11):723-7. PubMed ID: 19176004
[TBL] [Abstract][Full Text] [Related]
36. Comparison of Myelodysplastic Syndrome Prognostic Scoring Systems.
Bektaş Ö; Üner A; Eliaçık E; Uz B; Işık A; Etgül S; Bozkurt S; Haznedaroğlu İC; Göker H; Sayınalp N; Aksu S; Demiroğlu H; Özcebe Oİ; Büyükaşık Y
Turk J Haematol; 2016 Jun; 33(2):119-26. PubMed ID: 26376664
[TBL] [Abstract][Full Text] [Related]
37. Factors influencing survival in myelodysplastic syndromes in a Brazilian population: comparison of FAB and WHO classifications.
Lorand-Metze I; Pinheiro MP; Ribeiro E; de Paula EV; Metze K
Leuk Res; 2004 Jun; 28(6):587-94. PubMed ID: 15120935
[TBL] [Abstract][Full Text] [Related]
38. Report on outcomes of hypomethylating therapy for analyzing prognostic value of Revised International Prognostic Scoring System for patients with lower-risk myelodysplastic syndromes.
Lee YJ; Park SW; Lee IH; Ahn JS; Kim HJ; Chung JS; Shin HJ; Lee WS; Lee SM; Joo YD; Kim H; Lee HS; Kim YS; Cho YY; Moon JH; Sohn SK
Ann Hematol; 2016 Oct; 95(11):1795-804. PubMed ID: 27530461
[TBL] [Abstract][Full Text] [Related]
39. High flow cytometric scores identify adverse prognostic subgroups within the revised international prognostic scoring system for myelodysplastic syndromes.
Alhan C; Westers TM; Cremers EM; Cali C; Witte BI; Ossenkoppele GJ; van de Loosdrecht AA
Br J Haematol; 2014 Oct; 167(1):100-9. PubMed ID: 24976502
[TBL] [Abstract][Full Text] [Related]
40. Prognostic scoring systems for myelodysplastic syndromes (MDS) in a population-based setting: a report from the Swedish MDS register.
Moreno Berggren D; Folkvaljon Y; Engvall M; Sundberg J; Lambe M; Antunovic P; Garelius H; Lorenz F; Nilsson L; Rasmussen B; Lehmann S; Hellström-Lindberg E; Jädersten M; Ejerblad E
Br J Haematol; 2018 Jun; 181(5):614-627. PubMed ID: 29707769
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
